![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amedeo Res | LSE:AMED | London | Ordinary Share | GB00BZ0XVY42 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.50 | 2.00 | 5.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS No 7605n CHIROSCIENCE GROUP PLC 1st July 1997 CHIROSCIENCE ANNOUNCES CHANGES TO R&D RESPONSIBILITIES Chiroscience announces today the appointment of Dr Robert Jackson as Executive Director for Research and Development for its Darwin Discovery activities in the UK. Dr Jackson will be based in Cambridge, UK, and will report to Dr John Padfield, Chief Executive of Chiroscience Group plc, alongside Dr David Galas, Executive Director for Discovery Research for Darwin Discovery activities in the USA. Dr Jackson joins Chiroscience from Agouron where he was Vice President for Research and Development. Agouron is a major US biotechnology company with one of the leading R&D pipelines in the industry. Its first drug, for which Dr Jackson was responsible, has just been launched. Prior to joining Agouron in 1992, Dr Jackson held senior industrial positions in Du Pont Merck and Warner-Lambert over a 10 year period and academic positions in Indiana University, Scripps Clinic and the University of London Institute of Cancer Research. Bob Jackson is 54 and was educated in Cambridge and London before conducting post-doctoral research at Yale University School of Medicine. He is well recognised within the cancer field and has published widely, including research on matrix metalloproteinases. Dr Jackson will be responsible for all biological and chemical research and development, technical operations and clinical development activities in Cambridge and Stevenage. Dr Jon Dickens, who has been responsible for the pre- clinical research activities in Cambridge, has indicated his wish to leave Chiroscience to pursue other interests. He will act as a consultant to the Group on defined projects. Commenting, Dr John Padfield, Chief Executive of Chiroscience said, 'The growth in our applied research programmes, particularly in the exploitation of our investment in enzyme inhibitors through their development for a number of clinical end points, requires their leadership and co-ordination through one director. Bob Jackson's experience and record make him an ideal candidate for this role and I am delighted he has joined us. Jon Dickens has played a key role in research in helping Chiroscience reach this point. We wish him all success in his future career.' For further information please contact: Dr John Padfield, Chief Executive Matthew Hooper/Sarah Carrell Chiroscience Group plc Shandwick Consultants Tel: 01223 420430 Tel: 0171 329 0096 END
1 Year Amedeo Res Chart |
1 Month Amedeo Res Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions